How to buy Celyad Oncology stock | $5.52

Celyad Oncology SA is a biotechnology business based in the US. Celyad Oncology shares (CYAD) are listed on the NASDAQ and all prices are listed in US Dollars. Celyad Oncology employs 87 staff and has a trailing 12-month revenue of around 0.00.

Celyad Oncology stock price (NASDAQ: CYAD)

Use our graph to track the performance of CYAD stocks over time.

Celyad Oncology shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$5.52
52-week range	$4.01 - $10.60
50-day moving average	$5.01
200-day moving average	$6.55
Wall St. target price	$18.63
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-7.01

Buy Celyad Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Celyad Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Celyad Oncology SA by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Celyad Oncology price performance over time

Historical closes compared with the close of $5.52 from 2021-05-28

1 week (2021-07-21)	N/A
1 month (2021-07-01)	5.14%
3 months (2021-04-30)	-12.66%
6 months (2021-01-28)	N/A

1 year (2020-07-28)	N/A
2 years (2019-07-28)	N/A
3 years (2018-07-28)	N/A
5 years (2016-07-28)	N/A

Celyad Oncology financials

Revenue TTM	$2,500
Gross profit TTM	$5,000
Return on assets TTM	-23.34%
Return on equity TTM	-63.29%
Profit margin	0%
Book value	$1.78
Market capitalisation	$63.4 million

TTM: trailing 12 months

Shorting Celyad Oncology shares

There are currently 212,416 Celyad Oncology shares held short by investors – that's known as Celyad Oncology's "short interest". This figure is 2% down from 216,683 last month.

There are a few different ways that this level of interest in shorting Celyad Oncology shares can be evaluated.

Celyad Oncology's "short interest ratio" (SIR)

Celyad Oncology's "short interest ratio" (SIR) is the quantity of Celyad Oncology shares currently shorted divided by the average quantity of Celyad Oncology shares traded daily (recently around 32983.850931677). Celyad Oncology's SIR currently stands at 6.44. In other words for every 100,000 Celyad Oncology shares traded daily on the market, roughly 6440 shares are currently held short.

However Celyad Oncology's short interest can also be evaluated against the total number of Celyad Oncology shares, or, against the total number of tradable Celyad Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Celyad Oncology's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Celyad Oncology shares in existence, roughly 10 shares are currently held short) or 0.0216% of the tradable shares (for every 100,000 tradable Celyad Oncology shares, roughly 22 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Celyad Oncology.

Find out more about how you can short Celyad Oncology stock.

Celyad Oncology share dividends

We're not expecting Celyad Oncology to pay a dividend over the next 12 months.

Celyad Oncology share price volatility

Over the last 12 months, Celyad Oncology's shares have ranged in value from as little as $4.01 up to $10.6. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celyad Oncology's is 1.2941. This would suggest that Celyad Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Celyad Oncology overview

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. .

Frequently asked questions

What percentage of Celyad Oncology is owned by institutions?
Currently 6.999% of Celyad Oncology shares are held by institutions. How many people work for Celyad Oncology?
Latest data suggests 87 work at Celyad Oncology. When does the fiscal year end for Celyad Oncology?
Celyad Oncology's fiscal year ends in December. Where is Celyad Oncology based?
Celyad Oncology's address is: Axis Business Park, Mont-Saint-Guibert, Belgium, 1435 What is Celyad Oncology's ISIN number?
Celyad Oncology's international securities identification number is: US1512052002 What is Celyad Oncology's CUSIP number?
Celyad Oncology's Committee on Uniform Securities Identification Procedures number is: 151205200